S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
TSE:TRIL

Trillium Therapeutics - TRIL Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
C$23.33
C$23.33
52-Week Range
N/A
Volume
60,423 shs
Average Volume
166,586 shs
Market Capitalization
C$2.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TRIL stock logo

About Trillium Therapeutics (TSE:TRIL) Stock

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Viridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan Violin
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Leukemia Therapeutics Global Market Report 2022
Trillium Therapeutics Inc. News
Trillium Securityholders Approve Acquisition by Pfizer
Here's the Biotech Pfizer Should Consider Acquiring Next
Why Trillium Therapeutics Stock Is Skyrocketing Today
See More Headlines
Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$43,000.00
Book Value
C$2.17 per share

Miscellaneous

Free Float
N/A
Market Cap
C$2.45 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Dr. Jan Skvarka (Age 54)
    Pres, CEO & Director
    Comp: $812.5k
  • Mr. James T. Parsons C.A. (Age 56)
    C.P.A., MAcc, CPA-CA, Chief Financial Officer
    Comp: $543.38k
  • Dr. Robert Uger (Age 50)
    Chief Scientific Officer
    Comp: $595.73k
  • Dr. Penka Petrova (Age 53)
    Chief Devel. Officer
    Comp: $553.53k
  • Dr. Ingmar Bruns M.D. (Age 46)
    Ph.D., Chief Medical Officer
    Comp: $230k
  • Benjamin Looker
    Gen. Counsel
  • Dr. Rosemary Harrison (Age 38)
    Sr. VP of Corp. Devel. & Strategy
  • Dr. Michael G. Hill
    Head of Calgary Site
  • Ms. Kathleen Large (Age 61)
    Sr. VP - Clinical Operations













TRIL Stock - Frequently Asked Questions

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does Trillium Therapeutics make?

Trillium Therapeutics (TSE:TRIL) has a market capitalization of C$0.00 and generates C$43,000.00 in revenue each year.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The official website for the company is www.trilliumtherapeutics.com. The company can be reached via phone at +1-416-5950627.

This page (TSE:TRIL) was last updated on 3/23/2023 by MarketBeat.com Staff